Ergebnis der Suchanfrage nach Bad

STADA Arzneimittel AG

Press release: STADA continues strong growth journey in the first half of 2024

STADA Arzneimittel AG

Press release: Alvotech and STADA add to strategic alliance through denosumab partnership

Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...

STADA Arzneimittel AG

Press release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo

STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...

STADA Arzneimittel AG

Press release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey

STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...

STADA Arzneimittel AG

Press release: STADA continues with double-digit sales and profit growth in 2023

Leipzig Tourismus und Marketing GmbH

6

Explore Leipzig with New Digital Tours

STADA Arzneimittel AG

Press release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...

STADA Arzneimittel AG

Press release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner

STADA Arzneimittel AG

3

Press release: STADA further improves Sustainability ranking; rates among top 6% of pharma players globally

STADA Arzneimittel AG

Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio

STADA Arzneimittel AG

2

Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals

SGL Carbon SE

3

Press Release: Annual General Meeting approves all items on the agenda

Leipzig Tourismus und Marketing GmbH

5

Explore The Leipzig Region By Bike – Top 5 Routes

Deutsche Hospitality

5

Deutsche Hospitality appoints new management positions

OpenSynergy GmbH

LDRA and OpenSynergy partnership promotes a defence-in-depth strategy for embedded automotive applications

SEKRÈ mystery bag

A luxury handbag to celebrate the birthday of Grace Kelly

SEKRÈ mystery bag

Some of the world' s rarest handbags

SEKRÈ mystery bag

Handbags with a piece of world history

Deutsche Hospitality

6

press release: First MAXX by Steigenberger in Vienna

Helaba

Helaba reports best-ever Group Earnings Before Tax under IFRS in an amount of EUR 492 million

Frankfurt/Main (ots) - - Owners will receive a dividend of 8 per cent - Requirements of EBA and Basel III are satisfied - Regulatory environment requires portfolio adaptations and cost optimisation With Group earnings before tax in an amount of EUR 492 million, Helaba Landesbank Hessen-Thüringen ...

Fresenius SE & Co. KGaA

Fresenius achieves record Q3 earnings - improves 2011 earnings outlook

Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...